The July 2016 issue of MedicinMan with articles by Piyush Agarwal, K. Hariram, Vivek Hattangadi, Anjali Sharma, Chandan Kumar, RB Balakrishna and Pankaj Mehrotra

Opportunities for Indian Pharma

Articles by Bhaskar Chakravorty, Hanno Wolfram, K. Hariram, Krishna Singh, Shreenivas S, Chandan Kumar and Salil Kallianpur

Novo Nordisk’s Big Reset: What 9,000 Job Cuts Signal for Pharma’s Future

For years, Novo Nordisk was the poster child of growth. Its GLP-1 drugs, Ozempic and Wegovy, didn’t just change obesity treatment — they reshaped the company’s balance sheet. Demand outpaced supply, public awareness skyrocketed, and Novo’s market cap surged. But growth always attracts challengers. Enter Eli Lilly with Mounjaro and Zepbound, and a wave of competitors and compounded generics threatening margins. Add in slowing sales growth and operational bloat from years of expansion, and suddenly Novo’s leadership had to answer tough questions about sustainability.

Digital Transformation and the World of Pharma

A big myth about digital transformation is that it...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Indian Pharma: The Marketing – Field Disconnect and Its Remedy

The Anomaly Unless you learn to accept that chaos is...

The Tragic Genius of Yellapragada Subbarow

Every day, doctors worldwide prescribe methotrexate, doxycycline, and folic...

Private Equity Funds in Indian Healthcare: Who Wins? Who Loses?

The Two Headlines That Should Not Coexist Two recent news...

Gen Z Healthcare: Review of the Decoding Gen Z Report

Gen Z is not waiting to get sick. But...

Character: The Ultimate Differentiator in Healthcare and Pharma

My friend Salil Kallianpur, in his Substack post "The...

Marketing

Indian Pharma: The Marketing – Field Disconnect and Its Remedy

The Anomaly Unless you learn to accept that chaos is...

The Tragic Genius of Yellapragada Subbarow

Every day, doctors worldwide prescribe methotrexate, doxycycline, and folic...

Private Equity Funds in Indian Healthcare: Who Wins? Who Loses?

The Two Headlines That Should Not Coexist Two recent news...

Gen Z Healthcare: Review of the Decoding Gen Z Report

Gen Z is not waiting to get sick. But...

Character: The Ultimate Differentiator in Healthcare and Pharma

My friend Salil Kallianpur, in his Substack post "The...

Policies/Sales

Indian Pharma: The Marketing – Field Disconnect and Its Remedy

The Anomaly Unless you learn to accept that chaos is...

The Tragic Genius of Yellapragada Subbarow

Every day, doctors worldwide prescribe methotrexate, doxycycline, and folic...

Private Equity Funds in Indian Healthcare: Who Wins? Who Loses?

The Two Headlines That Should Not Coexist Two recent news...

Gen Z Healthcare: Review of the Decoding Gen Z Report

Gen Z is not waiting to get sick. But...

Character: The Ultimate Differentiator in Healthcare and Pharma

My friend Salil Kallianpur, in his Substack post "The...

Strategy

Indian Pharma: The Marketing – Field Disconnect and Its Remedy

The Anomaly Unless you learn to accept that chaos is...

The Tragic Genius of Yellapragada Subbarow

Every day, doctors worldwide prescribe methotrexate, doxycycline, and folic...

Private Equity Funds in Indian Healthcare: Who Wins? Who Loses?

The Two Headlines That Should Not Coexist Two recent news...

Gen Z Healthcare: Review of the Decoding Gen Z Report

Gen Z is not waiting to get sick. But...

Character: The Ultimate Differentiator in Healthcare and Pharma

My friend Salil Kallianpur, in his Substack post "The...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Customer Engagement and Experience are the New Differentiators

At the IDMA Marketing and Sales Conference in Mumbai...

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now

In September 2011, MedicinMan published a UCPMP Special Issue...

Pharma Digital Transformation – Leadership challenges

“Real digital transformation occurs when courageous leaders align goals...

IQVIA Sponsors Race for 7 to Commemorate World Rare Disease Day

“IQVIA is delighted to be associated for the fourth consecutive year as the main sponsor of Race for 7. While rare diseases, by virtue of their definition, affect relatively fewer number of patients, the overall number of rare disease patients is large enough to warrant more focused attention."